PF-06439535 (a Bevacizumab Biosimilar) Compared with Reference Bevacizumab (Avastin(®)), Both Plus Paclitaxel and Carboplatin, as First-Line Treatment for Advanced Non-Squamous Non-Small-Cell Lung Cancer: A Randomized, Double-Blind Study

BACKGROUND: PF-06439535 is a bevacizumab biosimilar. We aimed to compare the efficacy and safety of PF-06439535 with that of reference bevacizumab (Avastin(®)) sourced from the EU (bevacizumab-EU), each with paclitaxel and carboplatin, in the first-line treatment of advanced non-squamous non-small-c...

全面介紹

Na minha lista:
書目詳細資料
發表在:BioDrugs
Main Authors: Reinmuth, Niels, Bryl, Maciej, Bondarenko, Igor, Syrigos, Kostas, Vladimirov, Vladimir, Zereu, Manuela, Bair, Angel H., Hilton, Fiona, Liau, Katherine, Kasahara, Kazuo
格式: Artigo
語言:Inglês
出版: Springer International Publishing 2019
主題:
Original Research Article
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790355/
https://ncbi.nlm.nih.gov/pubmed/31338773
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40259-019-00363-4
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍